| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| F E Scheepers, C C Gispen de Wied, H E Hulshoff Pol, R S Kah. Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. The American journal of psychiatry. vol 158. issue 4. 2001-04-26. PMID:11282704. |
studies have found that caudate volume increased after treatment with typical antipsychotics in patients with schizophrenia but decreased after treatment was changed to clozapine. |
2001-04-26 |
2023-08-12 |
Not clear |
| Y W Lam, L Ereshefsky, G B Toney, C Gonzale. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. The Journal of clinical psychiatry. vol 62 Suppl 5. 2001-04-26. PMID:11305844. |
clozapine has been the treatment of choice for patients with refractory schizophrenia. |
2001-04-26 |
2023-08-12 |
Not clear |
| R F Squires, E Saederu. Additivities of compounds that increase the numbers of high affinity [3H]muscimol binding sites by different amounts define more than 9 GABA(A) receptor complexes in rat forebrain: implications for schizophrenia and clozapine research. Neurochemical research. vol 25. issue 12. 2001-04-19. PMID:11152388. |
additivities of compounds that increase the numbers of high affinity [3h]muscimol binding sites by different amounts define more than 9 gaba(a) receptor complexes in rat forebrain: implications for schizophrenia and clozapine research. |
2001-04-19 |
2023-08-12 |
rat |
| R L Findling, N K McNamara, B L Graciou. Paediatric uses of atypical antipsychotics. Expert opinion on pharmacotherapy. vol 1. issue 5. 2001-04-05. PMID:11249501. |
based on the available information, it appears that clozapine has a role in juvenile treatment resistant schizophrenia. |
2001-04-05 |
2023-08-12 |
Not clear |
| D A Revick. The new atypical antipsychotics: a review of pharmacoeconomic studies. Expert opinion on pharmacotherapy. vol 1. issue 2. 2001-04-05. PMID:11249546. |
the evidence, from a variety of studies, indicates that clozapine is a cost-effective treatment for neuroleptic refractory schizophrenia. |
2001-04-05 |
2023-08-12 |
Not clear |
| S K Kulkarni, I Nina. Dopamine D4 receptors and development of newer antipsychotic drugs. Fundamental & clinical pharmacology. vol 14. issue 6. 2001-03-29. PMID:11206702. |
the discovery of d4 receptors and the putative affinity of clozapine for d4 receptors have kindled development of selective d4 receptor antagonists for the treatment of schizophrenia. |
2001-03-29 |
2023-08-12 |
Not clear |
| E Spina, A Avenoso, M Salemi, G Facciolá, M G Scordo, M Ancione, A Madi. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry. vol 33. issue 6. 2001-03-08. PMID:11147928. |
the effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). |
2001-03-08 |
2023-08-12 |
Not clear |
| I Reznik, L Volchek, R Mester, M Kotler, I Sarova-Pinhas, B Spivak, A Weizma. Myotoxicity and neurotoxicity during clozapine treatment. Clinical neuropharmacology. vol 23. issue 5. 2001-03-08. PMID:11154096. |
in 2.1% of medically healthy patients with schizophrenia treated with clozapine on a long-term basis, signs of myotoxicity were found. |
2001-03-08 |
2023-08-12 |
Not clear |
| S Kapur, P Roy, J Daskalakis, G Remington, R Zipursk. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. The American journal of psychiatry. vol 158. issue 2. 2001-03-08. PMID:11156818. |
the authors added haloperidol, a potent d(2) blocker, to ongoing treatment with clozapine in patients with schizophrenia to determine the effects of this combination on dopamine d(2) receptor blockade, prolactin level, and extrapyramidal side effects. |
2001-03-08 |
2023-08-12 |
Not clear |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
the effect of clozapine on the speed and accuracy of information processing in schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
the study aimed to investigate the effects of clozapine on the speed and accuracy of information processing in patients with schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
symptom severity and performance on three timed tests of cognitive function were also measured prior to clozapine treatment in the schizophrenia group, and these measures were repeated during treatment with clozapine. |
2001-03-01 |
2023-08-12 |
human |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
treatment with clozapine was found to significantly improve reaction time and the accuracy of target detection in patients with schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| C A Galletly, C R Clark, A C McFarlane, D L Webe. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 24. issue 8. 2001-03-01. PMID:11125857. |
the results of this pilot study indicate that treatment with clozapine can produce limited improvement in cognitive function in schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| L Lahdelma, A Ahokas, L C Andersson, J Suvisaari, I Hovatta, M O Huttunen, S Koskimie. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199946. |
human leukocyte antigen-a1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. |
2001-03-01 |
2023-08-12 |
human |
| L Lahdelma, A Ahokas, L C Andersson, J Suvisaari, I Hovatta, M O Huttunen, S Koskimie. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199946. |
the authors have previously reported a significantly increased frequency of hla-a1 among patients with schizophrenia who do not respond to conventional drugs, but do respond to clozapine treatment. |
2001-03-01 |
2023-08-12 |
human |
| L Lahdelma, A Ahokas, L C Andersson, J Suvisaari, I Hovatta, M O Huttunen, S Koskimie. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199946. |
these results suggest that hla-a1 may predict a good therapeutic outcome and a low risk of agranulocytosis and, thus, enable defining a subgroup of patients with schizophrenia in whom clozapine treatment could be started early to stop the disease from progressing. |
2001-03-01 |
2023-08-12 |
human |
| M W Agelink, T Majewski, C Wurthmann, K Lukas, H Ullrich, T Linka, E Kliese. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199953. |
as part of a prospective clinical study investigating the effects of atypical neuroleptics on autonomic neurocardiac function (anf), serial standardized recordings of conventional electrocardiograms and computer-calculated measurements of 5-minute resting heart rate variability (hrv) were obtained from 51 medication-free inpatients with schizophrenia (dsm-iii-r-diagnosed) before and after an average of 14.1 days of treatment with amisulpride 400 mg/day (n = 12), olanzapine 20 mg/day (n = 13), sertindole 12 mg/day (n = 13), or clozapine 100 mg/day (n = 13). |
2001-03-01 |
2023-08-12 |
Not clear |
| K H Littrell, C G Johnson, N M Hilligoss, C D Peabody, S H Littrel. Switching clozapine responders to olanzapine. The Journal of clinical psychiatry. vol 61. issue 12. 2001-03-01. PMID:11206595. |
clozapine is an atypical antipsychotic indicated for the management of severely ill patients with schizophrenia who have failed to respond adequately to standard drug treatment. |
2001-03-01 |
2023-08-12 |
Not clear |
| M Dettling, C Sachse, J Brockmöller, J Schley, B Müller-Oerlinghausen, I Pickersgill, A Rolfs, R T Schaub, J Schmide. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology. vol 152. issue 1. 2001-02-15. PMID:11041319. |
clozapine is a unique antipsychotic drug, outstanding for its lack of extrapyramidal side-effects and its superior efficacy in refractory schizophrenia. |
2001-02-15 |
2023-08-12 |
Not clear |